COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports
-
Published:2023-08-24
Issue:
Volume:
Page:
-
ISSN:2036-7406
-
Container-title:Dermatology Reports
-
language:
-
Short-container-title:Dermatol Reports
Author:
D'Erme Angelo Massimiliano,
Fidanzi CristianORCID,
Romanelli Marco,
Dini Valentina,
Bagnoni Giovanni,
Janowska Agata
Publisher
PAGEPress Publications
Reference9 articles.
1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria [published online ahead of print, 2021 Sep 18]. Allergy. 2021;10.1111/all.15090. doi:10.1111/all.15090
2. Alizadeh Aghdam M, Knol EF, van den Elzen M, et al. Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria. Clin Exp Allergy. 2020;50(3):364-371. doi:10.1111/cea.13566
3. Bostan E, Zaid F, Karaduman A, et al. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study. J Cosmet Dermatol. 2021;20(11):3369-3375. doi:10.1111/jocd.14484
4. Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24 Suppl 2:S21-S40. doi:10.1016/j.cmi.2018.02.002
5. Passante M, Napolitano M, Dastoli S, et al. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19. Dermatol Ther. 2021;34(6):e15111. doi:10.1111/dth.15111